Efineptakin alfa: all 29 studies that test it
Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.
- Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)RecruitingNCT07200089Phase 1
- Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell TherapyCompletedNCT05075603Phase 1Results posted
- NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLCTerminatedNCT04984811Phase 2Results posted
- NT-I7 for Kaposi Sarcoma in Patients With or Without HIVTerminatedNCT04893018Phase 1Results posted
- NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid TumorsCompletedNCT04332653Phase 1/2Results posted
- High-Risk Skin Cancers With Atezolizumab Plus NT-I7TerminatedNCT03901573Phase 1/2Results posted
- rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and TemozolomideActive, not recruitingNCT03687957Phase 1/2Results posted
- Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent GlioblastomaActive, not recruitingNCT05465954Phase 2
- Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck CancerActive, not recruitingNCT05286060Phase 2
- GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) PatientsActive, not recruitingNCT05191784Phase 2
- Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid TumorsActive, not recruitingNCT05145907Phase 2
- A Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19Status unknownNCT04810637Phase 2
- NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal LeukoencephalopathyCompletedNCT04781309Early Phase 1
- Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19TerminatedNCT04730427Phase 1
- A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)Active, not recruitingNCT04600817Phase 2
- NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal AdenocarcinomaTerminatedNCT04594811Phase 1
- NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing SurgeryTerminatedNCT04588038Phase 1
- A Trial of NT-I7 in COVID-19 (SPESELPIS)TerminatedNCT04501796Phase 1
- Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)WithdrawnNCT04498325Phase 1
- Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed GlioblastomaWithdrawnNCT04065087Phase 1/2
- Vaccine Response With NT-I7WithdrawnNCT04054752Phase 1
- Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients With Advanced Solid TumorsCompletedNCT04001075Phase 1/2
- GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid TumorsCompletedNCT03733587Phase 1
- Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With GlioblastomaCompletedNCT03619239Phase 1
- Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT03478995Phase 1
- Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.Status unknownNCT03206138Not applicable
- Safety and Tolerability of GX-I7 in HPV-infected Female VolunteersCompletedNCT03144934Phase 1
- Clinical Trial of GX-I7 in Healthy VolunteersCompletedNCT02860715Phase 1
- Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade GliomasTerminatedNCT02659800Phase 1